Analytical range LOQ [Bioanalytics]

posted by Farmacevt – North Macedonia, 2021-12-22 23:02 (1292 d 06:49 ago) – Posting: # 22711
Views: 4,857

Thanks,
But when you say:

❝ At one extreme you may need to eliminate those subject periods that are affected, which may mean a complete loss of a subject for stats if this is a 222BE design, since only subjects who contribute with T and R should be in the stats analysis.


What is the rational for eliminating those subjects? According to my opinion excluding these subjects can not show that the subjects might have had pre-dose concentration below the LOQ with the given method. It will only reduce the power of the study, isn't it?


Edit: Standard quotes restored; see also this post #8[Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,427 posts in 4,929 threads, 1,680 registered users;
57 visitors (0 registered, 57 guests [including 13 identified bots]).
Forum time: 06:52 CEST (Europe/Vienna)

No matter what side of the argument you are on,
you always find people on your side
that you wish were on the other.    Thomas Berger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5